Nivolumab and Pembrolizumab Dosing Intervals Optimizing Cancer Treatment News 3 Mins Read36 Cody Peer, PhD, from the National Institutes of Health, is conducting a randomized research study comparing the dosing intervals of…
PRO in Pts With Rare Cancers: Pembrolizumab [2022] Immunotherapy 11 Mins Read8 PRO in Pts With Rare Cancers: Pembrolizumab [2022] Â Patient reported Outcome (PRO) in patients with rare cancers (rare diseases)…
